By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company MaxCyte, Inc.

MaxCyte, Inc. (MXCT.L)

LSE Market Data in GBP, Fundamentals in USD
£147.69
-£12.31
-7.69%
Last Update: 25 Jun 2025, 17:40
£157.02M
Market Cap
-499.44
P/E Ratio (TTM)
Forward Dividend Yield
£147.69 - £407.84
52 Week Range

MXCT.L Stock Price Chart

Explore MaxCyte, Inc. interactive price chart. Choose custom timeframes to analyze MXCT.L price movements and trends.

There is nothing to show.

MXCT.L Company Profile

Discover essential business fundamentals and corporate details for MaxCyte, Inc. (MXCT.L) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Devices

IPO Date

29 Mar 2016

Employees

114.00

CEO

Maher Masoud

Description

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT.L Financial Timeline

Browse a chronological timeline of MaxCyte, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Earnings released on 7 May 2025

EPS came in at -£0.08 surpassing the estimated -£0.10 by +27.41%, while revenue for the quarter reached £8.05M, missing expectations by -15.89%.

Earnings released on 11 Mar 2025

EPS came in at -£0.08 surpassing the estimated -£0.11 by +24.79%, while revenue for the quarter reached £6.95M, missing expectations by -23.26%.

Earnings released on 7 Nov 2024

EPS came in at -£0.08 surpassing the estimated -£0.13 by +35.18%, while revenue for the quarter reached £6.23M, missing expectations by -18.76%.

Earnings released on 7 Aug 2024

EPS came in at -£0.07 surpassing the estimated -£0.10 by +27.44%, while revenue for the quarter reached £8.24M, beating expectations by +30.78%.

Earnings released on 8 May 2024

EPS came in at -£0.07 surpassing the estimated -£0.10 by +26.38%, while revenue for the quarter reached £9.04M, beating expectations by +51.97%.

Earnings released on 13 Mar 2024

EPS came in at -£0.04 surpassing the estimated -£0.05 by +24.98%, while revenue for the quarter reached £12.40M, beating expectations by +17.39%.

Earnings released on 9 Nov 2023

EPS came in at -£0.09 falling short of the estimated -£0.08 by -8.04%, while revenue for the quarter reached £6.58M, missing expectations by -9.52%.

Earnings released on 10 Aug 2023

EPS came in at -£0.08 falling short of the estimated -£0.08 by -6.47%, while revenue for the quarter reached £7.14M, missing expectations by -14.99%.

Earnings released on 11 May 2023

EPS came in at -£0.07 surpassing the estimated -£0.09 by +25.65%, while revenue for the quarter reached £6.94M, beating expectations by +3.40%.

Earnings released on 16 Mar 2023

EPS came in at -£0.02 surpassing the estimated -£0.06 by +64.25%, while revenue for the quarter reached £10.13M, missing expectations by -1.22%.

Earnings released on 30 Sept 2022

EPS came in at -£0.05 surpassing the estimated -£0.08 by +43.25%, while revenue for the quarter reached £9.62M, beating expectations by +2.93%.

Earnings released on 30 Jun 2022

EPS came in at -£0.06 falling short of the estimated -£0.06 by -1.20%, while revenue for the quarter reached £7.91M, beating expectations by +4.35%.

Earnings released on 31 Mar 2022

EPS came in at -£0.03 surpassing the estimated -£0.05 by +40.51%, while revenue for the quarter reached £8.83M, beating expectations by +37.06%.

Earnings released on 31 Dec 2021

EPS came in at -£0.04, while revenue for the quarter reached £7.53M.

Earnings released on 30 Sept 2021

EPS came in at -£0.02 surpassing the estimated -£0.04 by +51.67%, while revenue for the quarter reached £7.50M, beating expectations by +6.09%.

Earnings released on 30 Jun 2021

EPS came in at -£0.04, while revenue for the quarter reached £5.15M.

Earnings released on 31 Mar 2021

EPS came in at -£0.06, while revenue for the quarter reached £4.70M.

Earnings released on 31 Dec 2020

EPS came in at -£0.03, while revenue for the quarter reached £6.25M.

Earnings released on 30 Sept 2020

EPS came in at -£0.03, while revenue for the quarter reached £5.24M.

MXCT.L Stock Performance

Access detailed MXCT.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

There is nothing to show.
MXCT.L
Company Name
Exchange
Market Currency
Report Currency
Price
Price Change
Percentage Change
50-Day Average Price
200-Day Average Price
Trading Volume
Market Capitalization
MXCT.L
2025
2024
2023
2022
2021
Revenue
Gross Profit
Earnings Before Interest and Taxes (EBIT)
Net Income
Total Current Assets
Total Assets
Total Liabilities
Net Debt
Total Equity
Cash Flow from Operating
Cash Flow from Investing
Cash Flow from Financing
Free Cash Flow

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More